Accelerating Product Development in Global Health

Lead Research Organisation: Liverpool School of Tropical Medicine

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.  The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers’ understanding of each other’s needs and capabilities.  This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ‘entrepreneurs in residence’ schemes.  Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.

Publications

10 25 50

publication icon
Adolfi A (2019) Functional genetic validation of key genes conferring insecticide resistance in the major African malaria vector, Anopheles gambiae. in Proceedings of the National Academy of Sciences of the United States of America

 
Title Rebecca Lennon Exhibition at Dilston Grove. London 
Description Preparing material for a video artwork installation. High resolution video footage and recordings were made of mosquitoes feeding to provide material for an abstract and poetic art film that will provide arresting imagery for projection in the converted church gallery. 
Type Of Art Artistic/Creative Exhibition 
Year Produced 2019 
Impact The video footage is being prepared for the installation and still images have been provided to the LSTM without copyright to be used for teaching and communication. 
URL https://www.rebeccalennon.co.uk/
 
Title Scientific advisor to Christine Poulson to develop ideas for novel 
Description Novel " An air that kills" features the use of mosquitoes for murder mystery theme for a lab based plot. Advice was given on how mosquitoes are bred, tested for infection and resistance, and consultation on the scientific authenticity of scenarios discussed. 
Type Of Art Creative Writing 
Year Produced 2019 
Impact Novel published by Lion Fiction worldwide in November 2019. Available from all good book stores and Amazon. currently in the top 1000 all time selling medical thrillers on Amazon 
URL http://www.christinepoulson.co.uk/
 
Description Anti-Vec
Amount £94,000 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 02/2019 
End 01/2020
 
Description Antigen Discovery NIH SBIR Grant
Amount $224,000 (USD)
Organisation Antigen Discovery Inc 
Sector Private
Country United States
Start 03/2018 
End 02/2019
 
Description BactiVac Catalyst Funding Project: Identification of correlates of protection against pneumococcal colonization
Amount £55,000 (GBP)
Organisation University of Birmingham 
Sector Academic/University
Country United Kingdom
Start 07/2018 
End 08/2019
 
Description BactiVac Pumppriming Grant
Amount £50,000 (GBP)
Funding ID MC_PC_17222 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 07/2018 
End 08/2019
 
Description Click-chemistry to enhance therapeutic efficacy and translational potential of the IgG-Fc
Amount £37,018 (GBP)
Organisation Centre for Excellence in Infectious Disease Research Innovations 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2019 
End 05/2020
 
Description Enceph-IG - Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults: A randomised double-blind placebo-controlled trial
Amount £2,731,532 (GBP)
Funding ID NIHR EME Project 17/60/67 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 09/2019 
End 09/2024
 
Description Exploiting glycosylation against COVID-19
Amount £185,675 (GBP)
Funding ID BB/V017772/1 
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 12/2020 
End 06/2022
 
Description IVCC
Amount £56,100 (GBP)
Organisation Bill and Melinda Gates Foundation 
Sector Charity/Non Profit
Country United States
Start 05/2018 
End 12/2018
 
Description IVCC contract
Amount £75,000 (GBP)
Organisation IVCC 
Sector Charity/Non Profit
Country United Kingdom
Start 07/2018 
End 03/2019
 
Description IVCC project award
Amount £18,000 (GBP)
Organisation IVCC 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2018 
End 07/2018
 
Description MRC CiC
Amount £650,000 (GBP)
Funding ID MC_PC_17167 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 08/2018 
End 09/2019
 
Description MRC CiC - AAV-vectored delivery of engineered monoclonal antibodies as a prophylactic strategy against bloodstage malaria
Amount £38,574 (GBP)
Funding ID not known 
Organisation Liverpool School of Tropical Medicine 
Sector Academic/University
Country United Kingdom
Start 03/2021 
End 02/2022
 
Description MRC P2D
Amount £125,000 (GBP)
Funding ID MC_PC_16078 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 05/2018 
End 06/2018
 
Description NIH-Small Business Innovation Research Grant
Amount $300,000 (USD)
Organisation National Institutes of Health (NIH) 
Sector Public
Country United States
Start 01/2018 
End 01/2019
 
Description P2D
Amount £64,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 09/2018 
End 12/2019
 
Description Preemptive discovery of insecticide cross-resistance mechanisms for next generation malaria control products
Amount £769,618 (GBP)
Funding ID MR/V001264/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 02/2021 
End 01/2024
 
Description Wellcome Trust Innovator Award
Amount £484,578 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 02/2018 
End 02/2019
 
Title GM mosquitoes expressing specific P450s 
Description Generation of GM Anopheles Gambia mosquitoes over expressing specific insecticide metabolising P450s 
Type Of Material Model of mechanisms or symptoms - non-mammalian in vivo 
Year Produced 2018 
Provided To Others? Yes  
Impact Mosquitoes are being used for commercial testing of volatile compounds in a genetic background of high P450 metabolism. The work will inform policy on the use of volatile compounds for malaria control. 
 
Title Geneticaly modified mosquito line created overexpressing Glutathione S-Transferase 
Description We have created mosquito lines that overexpress a GST thought to be responsible for resistance to a number of insecticide classes. These can be tested against alternative novel and repurposed compounds to gauge the likelihood of resistance already in the field or that may develop rapidly against these compounds. 
Type Of Material Model of mechanisms or symptoms - non-mammalian in vivo 
Year Produced 2017 
Provided To Others? Yes  
Impact To date, the tool has shown that GST can give rise to resistance to diagnostic doses of DDT. This is the first time that a direct in vivo relationship between an insecticide and a GST has been documented 
 
Title High throughput screen for anopheles 
Description Adapted software to analyse behaviour of Anopheles larvae 
Type Of Material Technology assay or reagent 
Year Produced 2018 
Provided To Others? Yes  
Impact We have provided proof of principle screens of compounds and selected repurposed pest and agricultural insecticides to identify novel active compounds against mosquitoes 
 
Description Antigen Discovery Partnership 
Organisation Antigen Discovery Inc
Country United States 
Sector Private 
PI Contribution The collaboration with ADI aims to identify novel protein-based vaccine candidates against pneumonia using the proteome array from Antigen Discovery and samples derived from our Experimental Human Challenge model with Pneumococcus. Dr Solórzano-Gonzalez received a 2-week one-to-one training at ADI where she gained knowledge about their technology and how to analyse the data generated from that platform. We provided 300 serum and nasal wash samples, from the EHPC model to be analysed on their platform.
Collaborator Contribution Antigen Discovery provided their panproteome pneumococcal microarray and contributed towards the second week of Carla's visit, in order to gain further knowledge of their platform.
Impact In January 2018 we were granted together with ADI a NIH-Small Business Innovation Research Grant ($300,000) for analysing a total of 300 serum and nasal wash samples derived from our human model in ADI's platform. All the data has been analysed and a manuscript is in preparation.
Start Year 2018
 
Description Collaborating with Abaxon Biologics 
Organisation Abaxon Biologics
Country United Kingdom 
Sector Private 
PI Contribution Discussion are on-going with licensing monomeric-Fc patents covering new therapies for neurology
Collaborator Contribution Due diligence
Impact None as yet
Start Year 2018
 
Description Developing blockers of Zika infection 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Collaboration with Professor Alain Kohl
Collaborator Contribution Will test our hypersialyaletd Fc fragments at controlling viruses
Impact none yet
Start Year 2019
 
Description Hypersialylated blockers of Zika virus (ZIKV) infectivity and neuropathology. 
Organisation University of Glasgow
Department Institute of Infection, Immunity and Inflammation
Country United Kingdom 
Sector Academic/University 
PI Contribution We are testing hypersialylated Fc molecules for controlling Zika mediated neurodegeneration
Collaborator Contribution Provide virus models of neural degeneration
Impact too early
Start Year 2018
 
Description Prospective liability of novel and repurposed compounds to metabolic resistance in An. gambiae (3) 
Organisation CE Bioscience Ltd
Country United Kingdom 
Sector Private 
PI Contribution We lead a research project examining the genetics of insecticide resistance in msoquitoes. We perform functional genetic modification to examine the role of different gene families in resistacne phenotypes, in order to develop methods and compounds to overcome this resistance.
Collaborator Contribution The partners have developed a high throughput rapid screen of larval susceptibility to compounds based on image analysis of multiwell plates of larvae to monitor behaviour and death.
Impact Successful application for an MRC iCASE Studentship to develop the system further. The collaboration is multidisciplinary involving biological, physiochemcal and computational analysis to provide both qualitative and quantitative analysis.
Start Year 2017
 
Description collaboration with CeBiosciences 
Organisation CE Bioscience Ltd
Country United Kingdom 
Sector Private 
PI Contribution Joint project to examine high throughput larval assays for mosquitos. PhD student undertook 10 visits to use facilities at Cebiosciences.
Collaborator Contribution Cebiosciences provided expertise in hardware usage and access to IP regulated software for analysis
Impact Publications: Nature: The screen of repurposed chemicals is included in a Nature article (14/11/18) with co-authors from both partners. 'Improved reference genome of Aedes aegypti informs arbovirus vector control'.10.1038/s41586-018-0692-z Draft Manuscript in prep for PLOS NTD: Automated phenotyping of mosquito larvae enables high-throughput screening for novel larvicides and smartphone-based detection of larval insecticide resistance Presentations: 3 presentations and poster at Pyrethrum conference Cambridge Sept 3- 5 2018 Gareth Lycett: invited talk - Developing a toolkit for genetic analysis and control of malarial vectors David Sattelle: invited talk - Automated phenotyping for larvicidal screening and detection of resistance Beth Poulton: turbo talk and poster - Rapid, automated insecticide resistance analysis in mosquito larvae Awards A new MRC P2D project between LSTM (vector/parasitology groups )and CeBiosciences has been awarded: Examining snake venom peptides as novel reagents to address the burgeoning global threat to health and agriculture of pesticide-resistance Amount Awarded: £64,085.33
Start Year 2017
 
Title CHIMERIC FC RECEPTOR BINDING PROTEINS AND USES THEREOF 
Description The present invention relates to chimeric proteins, to compositions comprising such proteins and to the medical uses of such proteins and compositions. In particular the proteins or compositions of the invention may be used in the prevention or treatment of autoimmune diseases or inflammatory diseases, or for the prevention or treatment of diseases mediated through binding of sialic acid dependent receptors, or as vaccines or as anti-cancer agents. One aspect of the invention relates to a chimeric Fc receptor binding protein which comprises two chimeric polypeptide chains, wherein each chimeric polypeptide chain comprises an immunoglobulin G heavy chain constant region, a tailpiece region and a hinge region, wherein the amino acid sequence of each polypeptide chain possess a sugar moiety at or close to the N-terminus and a sugar moiety at or close to the C- terminus, and their use in the treatment or prevention of a disease mediated by a pathogen that relies on sialic acid receptors interactions. 
IP Reference WO2019175605 
Protection Patent application published
Year Protection Granted 2019
Licensed Commercial In Confidence
Impact Currently in negotiations for licensing
 
Title FUSION PROTEIN COMPRISING MULTIPLE HINGE SEQUENCES 
Description The invention relates to fusion polypeptides derived from IgG. The fusion polypeptides comprise a domain derived from an immunoglobulin heavy chain constant region; and a plurality of hinge regions derived from IgG hinge sequences. The invention also relates to nucleic acids encoding the fusion polypeptides, and to proteins comprising two fusion polypeptides of the invention. Also provided are a pharmaceutical composition comprising a fusion polypeptide and/or protein of the invention, and medical uses of the polypeptides, proteins, or compositions. 
IP Reference WO2019175606 
Protection Patent application published
Year Protection Granted 2019
Licensed No
Impact New approaches to deliver antigens that don't interfere with receptor binding
 
Title HexaGard UK00003018151 
Description A drug name for hexameric Fc fusion 
IP Reference  
Protection Trade Mark
Year Protection Granted 2013
Licensed Yes
Impact This patent has been licensed to UCB Pharma for further development and they are talking it into national phase. We now collaborate with UCB Pharma
 
Title IMMUNOMODULATORY PROTEINS 
Description A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject. 
IP Reference US2018362600 
Protection Patent application published
Year Protection Granted 2018
Licensed Yes
Impact To UCB pharma from 2015-2017. To be licensed to CSL Behring from mid 2019
 
Title IMMUNOMODULATORY PROTEINS 
Description A method for treatment of a mammalian subject for an autoimmune or inflammatory disease, the method comprising: administering to the mammalian subject an effective amount of a polymeric protein comprising five, six or seven polypeptide monomer units; wherein each polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit; wherein the polymeric protein does not comprise a further immunomodulatory portion; or an antigen portion that causes antigen-specific immunosuppression when administered to the mammalian subject. 
IP Reference WO2014060712 
Protection Patent granted
Year Protection Granted 2014
Licensed Yes
Impact Non-exclusively licensed to UCB Pharma Patent has now been granted unopposed in Europe
 
Title MONOMERIC PROTEINS AND USES THEREOF 
Description Provided are proteins comprising two chimeric polypeptide chains; wherein each chimeric polypeptide chain comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions; and an immunoglobulin tailpiece region. The amino acid sequence and glycosylation of the tailpiece region of the proteins is adapted, as compared to the sequence and glycosylation of wild-type immunoglobulin, to inhibit polymerisation of the protein. The adaptation of the amino acid sequence may be the loss of a cysteine residue, for example the cysteine residue corresponding to residue 248 of SEQ ID NO: 1. The proteins may be used in intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG) therapy. They may be used in the prevention or treatment of a disease mediated through binding of sialic acid-dependent receptors. Proteins of the invention may be used in the prevention and/or treatment of autoimmune or inflammatory diseases. The proteins may be conjugated to an immune modulator, and in such cases are suitable for vaccine use. 
IP Reference WO2017191439 
Protection Patent application published
Year Protection Granted 2017
Licensed Commercial In Confidence
Impact Publication see Journal of Immunology 2018
 
Title Murine antibodies 
Description A mouse fusion protein comprising two chimeric polypeptide chains each comprising two murine IgG heavy chain chains having an immunoglobulin tailpiece from, or derived from, a non-native immunoglobulin and wherein the amino acid sequence of each of the IgG heavy chain constant regions comprises an amino acid modification (e.g. M84C) which promotes the multimerisation or polymerisation of the fusion protein. Preferably the tailpiece is human and is derived from IgM or IgA and has a substitution or deletion at residue C17. Preferably, each chimeric chain comprises one or more murine hinge regions and a targeting moiety such as an ntigen binding region, small molecule or nucleic acid. The invention further relates to the uses of the fusion protein to detect a target molecule in a sample, preferably as a means for diagnosis such as blood group haemagglutination. 
IP Reference GB2572008 
Protection Patent application published
Year Protection Granted 2019
Licensed No
Impact none as yet
 
Title POLYMERIC PROTEINS AND USES THEREOF 
Description Provided are polymeric proteins that comprise two or more polypeptide monomer units, each monomer unit comprising two chimeric protein chains. Each chimeric polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions,wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit. Each chimeric protein chain also comprises a modified immunoglobulin M tailpiece region, wherein the amino acid sequence of each chimeric polypeptide monomer comprises an alteration of the primary structure as compared to the native sequences from which the immunoglobulin G heavy chain constant region or immunoglobulin M tailpiece region are derived, and the alteration changes the number of glycosylation sites in a manner that promotes polymerisation. This promotion of polymerisation may lead to the generation of tetrameric, hexameric, and even dodecameric forms of the proteins. The proteins are suitable formedical uses,such as in the prevention or treatment of autoimmune diseases such as idiopathic thrombocytopenia. Also provided are methods of treatment using the polymeric proteins, and pharmaceutical compositions comprising the polymeric proteins. 
IP Reference WO2016009232 
Protection Patent application published
Year Protection Granted 2016
Licensed Commercial In Confidence
Impact N/A
 
Description Elimination 8 workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Project was presented as part of a state of the art training in current entomological methods.
Year(s) Of Engagement Activity 2018
URL http://malariaelimination8.org
 
Description Glycan engineering for vaccines presented at Pirbright 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact BSI frontiers in human immunology antibody discovery
Year(s) Of Engagement Activity 2018
URL https://www.immunology.org/events/frontiers-in-human-and-veterinary-antibody-discovery
 
Description International Conference 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Invited Speaker 19th May 2018. 11th International Congress on Autoimmunity. Lisbon. Invited by Fabian Kasermann CSL Behring. N-terminal hinge glycosylation brings novel receptor binding properties to human IgG1-Fc multimers and monomers.
Year(s) Of Engagement Activity 2018
URL https://autoimmunity.kenes.com/2018#.W8CDcS2ZNBy
 
Description Interview with Proteogenix 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Spoke and wrote about my thoughts on antibodies and their role in controlling Sars-CoV-2
Year(s) Of Engagement Activity 2020
URL https://www.proteogenix.science/scientific-corner/antibody-production/interview-professor-richard-pl...
 
Description Invited Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact 19th September 2018. IITM Perspectives Meeting: Biologics as Therapeutics. Invited by Profs. Chris Tang and Helen McShane. University of Oxford. N-terminal hinge glycosylation for novel receptor interactions of IgG Fc monomers and multimers . University of Oxford doctoral training programme. I provided the wisdom of my experience about translating research.
Year(s) Of Engagement Activity 2018
URL https://iitmoxford.files.wordpress.com/2018/09/booklet_iitm_symposium-2018.pdf
 
Description Invited Speaker: Mosquito Research - From Sensory Biology to Vector Control 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Workshop on using research into sensory biology for vector control
Year(s) Of Engagement Activity 2019
 
Description Poster presentation and participation in IVCC Stakeholder meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Poster presentation and networking discussions with members of industry, policy-makers and field operatives involved in the production of new tools to control mosquitoes and malaria
Year(s) Of Engagement Activity 2019
 
Description Presentation to the Wellcome Trust 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Presented my translational activity to the Wellcome Trust as part of a successful bid for Wellcome Trust Translational Partnership Funding
Year(s) Of Engagement Activity 2019
 
Description Presented our work at British Society for Parasitology 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented talk "Glycan engineering of the IgG1-Fc for therapeutic and vaccine applications
Year(s) Of Engagement Activity 2018
URL https://www.lstmed.ac.uk/news-events/news/the-british-society-for-parasitology-autumn-symposium-in-l...
 
Description Presented our work at the British Society for Immunology 2019 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented our work at the BSI meeting held in Liverpool
Year(s) Of Engagement Activity 2019
URL https://www.bsicongress.com/bsi/frontend/reg/titem.csp?pageID=1399&eventID=2&eventID=2
 
Description School entrepreneur visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Schools
Results and Impact Award winning school children that had invented and trying to market novel approaches to disease control visited the dept to examine the transgenic mosquito colonies we have generated that feature in this award.
Year(s) Of Engagement Activity 2018
 
Description Seminar 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact My seminar on my Wellcome Trust research is available to view at:
https://www.lstmed.ac.uk/news-events/seminars-and-lectures/engineering-the-igg1-fc-for-enhanced-therapeutic-applications-a
Year(s) Of Engagement Activity 2019
URL https://www.lstmed.ac.uk/news-events/seminars-and-lectures/engineering-the-igg1-fc-for-enhanced-ther...
 
Description Webinar for Vellore Institute of Technology, India 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Undergraduate students
Results and Impact The Webinar "Preemptive discovery of insecticide cross-resistance mechanisms for next generation malaria control products" was on the invitation of the VIT Centre for Nanobiotechnology as part of the VIT-CNBT International Webinar Series. The purpose was to present the latest research being done in my group in the area of mosquito control. Around 50 people attended and there were a number of questions and discussion around the use of chemicoproteomic approaches for mapping resistance mechanisms.
Year(s) Of Engagement Activity 2021
 
Description Work highlighted by Genetic Engineering & Biotechnology News 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Our Wellcome Trust funded work on influenza was highlighted
Year(s) Of Engagement Activity 2019
URL https://www.genengnews.com/news/influenza-drug-platform-could-yield-candidates-for-multiple-pathogen...
 
Description Work highlighted in the journal Nature 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Our work was highlighted by Nature
Year(s) Of Engagement Activity 2019
URL https://www.nature.com/magazine-assets/d41586-019-02753-8/d41586-019-02753-8.pdf
 
Description new anti-influenza drugs highlighted by Science Daily 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact https://www.sciencedaily.com/releases/2019/01/190125120114.htm
Year(s) Of Engagement Activity 2019
URL https://www.sciencedaily.com/releases/2019/01/190125120114.htm
 
Description pyrethrum conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Gareth Lycett: invited talk - Developing a toolkit for genetic analysis and control of malarial vectors
Year(s) Of Engagement Activity 2018
 
Description turbo talk and poster international conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact PhD student on project Beth Poulton: turbo talk and poster - Rapid, automated insecticide resistance analysis in mosquito larvae
Year(s) Of Engagement Activity 2018
 
Description visit by Finance staff London School of Tropical Medicine and Hygiene 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Visit by the LSTMH finance dept to provide them with an overview of the research taking place in my lab and vector group to generate cross institute interest in our respective research priorities
Year(s) Of Engagement Activity 2019
 
Description visit by Research England 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact A visit to the insectaries to discuss the work being done in the dept under funding from UKRI, and wider issues of research policy
Year(s) Of Engagement Activity 2018